Cargando…
Angiotensin receptor-neprilysin inhibitor in patients with heart failure and chronic kidney disease
Despite significant advances in the management of heart failure with reduced ejection fraction (HFrEF), there remains an enormous health problem with high morbidity and mortality over the last few decades. The neprilysin inhibitor enhances the activity of natriuretic peptides, producing vasodilation...
Autores principales: | Cho, In-Jeong, Kang, Seok-Min |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Korean Society of Nephrology
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8685363/ https://www.ncbi.nlm.nih.gov/pubmed/34922429 http://dx.doi.org/10.23876/j.krcp.21.900 |
Ejemplares similares
-
Angiotensin receptor-neprilysin inhibitors: clinical potential in heart failure and beyond
por: Singh, Jagdeep SS, et al.
Publicado: (2015) -
Angiotensin Receptor-Neprilysin Inhibition (ARNI) in Heart Failure
por: Greenberg, Barry
Publicado: (2020) -
Chronic kidney disease, heart failure and neprilysin inhibition
por: Haynes, Richard, et al.
Publicado: (2020) -
Angiotensin receptor-neprilysin inhibitor for the treatment of heart failure: a review of recent evidence
por: Choi, Hong-Mi, et al.
Publicado: (2020) -
Effects of angiotensin receptor‐neprilysin inhibitor on insulin resistance in patients with heart failure
por: Kashiwagi, Yusuke, et al.
Publicado: (2023)